PE20100471A1 - Composicion de liberacion pulsatil de sildenafil y proceso para prepararla - Google Patents

Composicion de liberacion pulsatil de sildenafil y proceso para prepararla

Info

Publication number
PE20100471A1
PE20100471A1 PE2009001294A PE2009001294A PE20100471A1 PE 20100471 A1 PE20100471 A1 PE 20100471A1 PE 2009001294 A PE2009001294 A PE 2009001294A PE 2009001294 A PE2009001294 A PE 2009001294A PE 20100471 A1 PE20100471 A1 PE 20100471A1
Authority
PE
Peru
Prior art keywords
sidenafil
polymer
sodium
fraction
sildenafil
Prior art date
Application number
PE2009001294A
Other languages
English (en)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of PE20100471A1 publication Critical patent/PE20100471A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA DE SIDENAFIL DE LIBERACION PULSATIL QUE COMPRENDE UNA FRACCION DE LIBERACION INMEDIATA QUE CONTIENE DE 5 A 100 MG DE SIDENAFIL Y UNA FRACCION DE LIBERACION CONTROLADA QUE CONTIENE DE 25 A 150 MG DE SIDENAFIL, DONDE LA FRACCION DE LIBERACION CONTROLADA ESTA COMPUESTA POR PARTICULAS RECUBIERTAS QUE CONTIENEN: a) UN AGENTE SUPERDESINTEGRANTE TAL COMO CROSPOVIDONA, CROSCARMELOSA SODICA Y ALMIDON GLICOLATO DE SODIO, b) UN RECUBRIMIENTO FORMADO POR UN POLIMERO DE SOLUBILIDAD PH-DEPENDIENTE TAL COMO COPOLIMEROS DEL ACIDO METACRILICO, FTALATO DE CELULOSA, ENTRE OTROS, Y UN POLIMERO DE SOLUBILIDAD PH-INDEPENDIENTE TAL COMO COPOLIMEROS DE AMONIO METACRILATO, ETILCELULOSA, POLIVINILACETATO, ENTRE OTROS, Y c) OPCIONALMENTE OTROS EXCIPIENTES. DICHA COMPOSICION CONTIENE UNA CANTIDAD DE SILDENAFILO MAYOR AL 45%. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION
PE2009001294A 2008-12-12 2009-12-07 Composicion de liberacion pulsatil de sildenafil y proceso para prepararla PE20100471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/003466 WO2010067140A1 (es) 2008-12-12 2008-12-12 Composicion de liberacion pulsatil de sildenafil y proceso para prepararla

Publications (1)

Publication Number Publication Date
PE20100471A1 true PE20100471A1 (es) 2010-07-22

Family

ID=42242382

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009001294A PE20100471A1 (es) 2008-12-12 2009-12-07 Composicion de liberacion pulsatil de sildenafil y proceso para prepararla

Country Status (13)

Country Link
US (1) US20110244050A1 (es)
EP (1) EP2374460A4 (es)
AR (1) AR071970A1 (es)
BR (1) BRPI0823356A2 (es)
CL (1) CL2009002173A1 (es)
CR (1) CR20110322A (es)
EC (1) ECSP11011194A (es)
MX (1) MX339136B (es)
NI (1) NI201100119A (es)
PA (1) PA8853801A1 (es)
PE (1) PE20100471A1 (es)
UY (1) UY32304A (es)
WO (1) WO2010067140A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498441B2 (en) 2012-01-27 2016-11-22 Siegfried Rhein S.A. De C.V. Nitazoxadine composition and process to prepare same
EA019381B1 (ru) * 2012-07-20 2014-03-31 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Таблетка, содержащая ингибитор фосфодиэстеразы пятого типа, способ ее получения и ее применение
KR101340733B1 (ko) * 2012-12-31 2013-12-12 (주) 에프엔지리서치 신규한 마이크로그래뉼 제형
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2023037394A1 (en) * 2021-09-13 2023-03-16 Amman Pharmaceutical Industries Company A pharmaceutical composition of sildenafil and a formulation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
TR199901564T2 (xx) 1997-01-06 1999-09-21 Pfizer Inc. H�zl� ��z�lebilen ve tat-maskesi sa�layan dozaj ispen�iyari formu.
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US8512751B2 (en) * 2004-12-20 2013-08-20 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
KR20140114887A (ko) * 2006-08-31 2014-09-29 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템

Also Published As

Publication number Publication date
NI201100119A (es) 2012-08-03
MX339136B (es) 2016-05-13
EP2374460A4 (en) 2013-08-21
MX2011005752A (es) 2011-08-12
WO2010067140A1 (es) 2010-06-17
UY32304A (es) 2010-05-31
CR20110322A (es) 2011-10-25
EP2374460A1 (en) 2011-10-12
BRPI0823356A2 (pt) 2015-06-16
ECSP11011194A (es) 2011-09-30
PA8853801A1 (es) 2010-07-27
AR071970A1 (es) 2010-07-28
US20110244050A1 (en) 2011-10-06
CL2009002173A1 (es) 2010-04-09

Similar Documents

Publication Publication Date Title
PE20100471A1 (es) Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
CY1123334T1 (el) Σκευασματα φιναστεριδης για αποδεσμευση φαρμακου στα μαλλια και στο τριχωτο της κεφαλης
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
EA201892836A1 (ru) Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением
UA106877C2 (uk) Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
BR112013025519A2 (pt) composição farmacêutica
EA201100969A1 (ru) Солевые формы органического соединения
PE20201496A1 (es) Composiciones y metodos para tratar anemia
AR088524A1 (es) Composicion descongelante, proceso de preparacion, conjunto de parte y uso
PE20080661A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa
CL2011002964A1 (es) Composicion para controlar enfermedades de plantas que comprende acido 4-oxo-4-[(2-feniletilamino]-butirico y un inhibidor ajeno a quinona; agente de tratamiento de semillas; y uso.
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
MX2010007672A (es) Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion.
CL2008003699A1 (es) Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas.
UA93530C2 (ru) Композиция c пролонгированным высвобождением активного вещества, способ ee получения и применения
ATE542525T1 (de) Verbesserte pharmazeutische zusammensetzung mit einem pyrrolidon-antikonvulsivum und verfahren zu seiner herstellung
AR055953A1 (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
TN2016000170A1 (en) Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid.
WO2014111956A3 (en) Sustained release formulations of curcuminoids and method of preparation thereof
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
SG10201803996WA (en) Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
PL408608A1 (pl) Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
RS53960B1 (en) NEW COMPOSITION FOR TREATMENT OF ESSENTIAL THROMBOCYTEMIA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal